Clinical trial for Non-Small Cell Lung Cancer
Official title FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
ClinicalTrials.gov ID: NCT07216105
What this study is testing
What is FT836?
FT836 is an investigational intravenous drug being studied for the treatment of non‑small cell lung cancer.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to see how safe FT836 is and find the best dose for future trials, with or without chemotherapy and the antibodies trastuzumab or cetuximab.
- Who it's for
- Adults with advanced non‑small cell lung cancer, colorectal cancer, breast cancer, ovarian cancer, endometrial carcinoma, or head and neck squamous cell carcinoma.
- What's involved
- Participants will receive FT836, sometimes together with chemotherapy and/or the antibodies trastuzumab or cetuximab, and will have regular medical visits and tests to monitor safety.
- Time commitment
- The trial lasts several weeks to months, with scheduled visits for dosing, monitoring, and safety assessments.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- For all regimens, disease that is not amenable to curative therapy and that has relapsed or progressed following at least one line of prior systemic...
- Absolute neutrophil count (ANC) \>1000/µL without growth factor support within 7 days prior to start of first study intervention
- Platelet count ≥75,000/µL without transfusion support within 14 days prior to start of first study intervention
- Estimated creatinine clearance ≥50 mL/minute by Cockcroft-Gault method or other standard institutional method
- Total bilirubin ≤1.5 × upper limit of normal (ULN); for participants with documented Gilbert syndrome, total bilirubin must be ≤3 ×ULN
You likely can't join if
- Clinically significant cardiovascular disease including any of the following: uncontrolled/ unstable cardiac arrhythmias, myocardial infarction...
- Receipt of any biological therapy, chemotherapy, investigational therapy, or radiation therapy within 2 weeks or five half-lives prior to start of...
- Known active central nervous system (CNS) involvement by malignancy.
- Non-malignant CNS disease such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease or receipt of medications for these conditions...
- Currently receiving or likely to require systemic immunosuppressive therapy (e.g., prednisone ≥5 mg daily) for any reason from start of first study...
- Any history of Grade ≥3 immune-related AE or Grade ≥2 eye toxicity attributed to prior cancer immunotherapy, other than endocrinopathy managed with...
See the full eligibility criteria
- For all regimens, disease that is not amenable to curative therapy and that has relapsed or progressed following at least one line of prior systemic therapy.
- Absolute neutrophil count (ANC) \>1000/µL without growth factor support within 7 days prior to start of first study intervention
- Platelet count ≥75,000/µL without transfusion support within 14 days prior to start of first study intervention
- Estimated creatinine clearance ≥50 mL/minute by Cockcroft-Gault method or other standard institutional method
- Total bilirubin ≤1.5 × upper limit of normal (ULN); for participants with documented Gilbert syndrome, total bilirubin must be ≤3 ×ULN
- Aspartate transaminase (AST) ≤3 × ULN or alanine transaminase (ALT) ≤3 × ULN; in participants with documented liver metastases, AST or ALT ≤5 × ULN
- Alkaline phosphatase (ALP) ≤2.5 × ULN; in participants with documented liver or bone metastases, ALP ≤5 × ULN
- Oxygen saturation \>90% on room air
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.
- Presence of measurable disease by RECIST, v1.1 assessed within 28 days prior to start of first study intervention.
- Presence of baseline safely accessible lesions of adequate size for on-treatment biopsies (exceptions for lesion size may be granted with medical monitor approval) and participant willingness to undergo protocol...
- Clinically significant cardiovascular disease including any of the following: uncontrolled/ unstable cardiac arrhythmias, myocardial infarction within 6 months prior to start of first study intervention, unstable angina...
- Receipt of any biological therapy, chemotherapy, investigational therapy, or radiation therapy within 2 weeks or five half-lives prior to start of first study intervention, whichever is shorter.
- Known active central nervous system (CNS) involvement by malignancy. Participants with prior CNS involvement from their malignancy must have completed effective treatment of their CNS disease with no symptoms of disease...
- Non-malignant CNS disease such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease or receipt of medications for these conditions within 6 months prior to study enrollment.
- Currently receiving or likely to require systemic immunosuppressive therapy (e.g., prednisone ≥5 mg daily) for any reason from start of first study intervention to Day 29 with the exception of corticosteroids as a...
- Any history of Grade ≥3 immune-related AE or Grade ≥2 eye toxicity attributed to prior cancer immunotherapy, other than endocrinopathy managed with replacement therapy or asymptomatic elevation of serum amylase or...
- Grade ≥2 peripheral neuropathy limiting instrumental activities of daily living.
The study team makes the final eligibility decision.
Where it is enrolling
- La Jolla, California, United States
- Los Angeles, California, United States
- Minneapolis, Minnesota, United States
- Philadelphia, Pennsylvania, United States
- Houston, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at La Jolla, California, United States; Los Angeles, California, United States; Minneapolis, Minnesota, United States; Philadelphia, Pennsylvania, United States; Houston, Texas, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.